Hints and tips:
Related Special Reports
...“Misaligned incentives across the US healthcare system have led to meaningful delays and barriers to biosimilar adoption, resulting in significant missed opportunities for healthcare savings,” the Swiss...
...Chris Meekins, analyst at Raymond James & Associates, said Merck was the first but probably not the last big drugmaker that would challenge the government....
...Ginger Graham, a board member since 2010 and former chief of Amylin Pharmaceuticals, will fill the chief executive role while it searches for “a successor with deep healthcare experience”....
...For the GSK legal team, this meant recasting itself to support a smaller, more focused pharmaceutical business....
...AbbVie and Eli Lilly have withdrawn from the deal after the German conglomerate Bayer’s pharmaceutical chief executive told the Financial Times on Monday that it was reducing its UK footprint and cutting...
...Amgen is close to a deal to acquire Horizon Therapeutics in a transaction worth as much as $20bn, according to sources familiar with the matter, as a sell-off in healthcare stocks creates attractive targets...
...Its talent acquisition lead James Girling recently aimed a post on LinkedIn at tech workers fired by Twitter....
...However, large pharmaceutical and healthcare companies — including those such as J&J that have benefited from the cash generated by Covid-19 vaccine sales — have been in a better position to strike deals...
...Bayer shuns ‘innovation unfriendly’ Europe The German pharmaceutical company has said it is shifting the focus of its drugs business to the US and away from Europe, where governments are making “big mistakes...
...“As we’ve stated from the outset, this transaction is procompetitive, will advance innovation, lower healthcare costs and save lives....
...Accordingly, big pharma groups like Pfizer, Bayer and Regeneron have taken note, forming partnerships with the pioneers....
...Procter & Gamble has been considering adding more consumer healthcare assets to its portfolio of products, they said....
...Keytruda will cost the American healthcare system about $137bn during that eight-year period, I-MAK claims....
...Disease Control and Prevention on Thursday backed boosters for some of those groups, but rejected endorsing a third jab for those working in jobs with high risk of exposure to Covid, including retail and healthcare...
...Some healthcare workers fear a repeat of confusion in December, when vaccine sites did not have enough staff to administer the jabs they were being given and millions of doses were left to languish in freezers...
...But Dr Carrie Teicher, director of programmes at Médecins Sans Frontières in the US, said officials should be “moving mountains” to ensure available doses go to protect healthcare workers and the vulnerable...
...“These companies continued to profit off the misery, death and destruction nationwide and today we put an end to it,” said Letitia James, New York attorney-general....
...In 2015, Welsh entrepreneur James Koash began treatment for sleep apnoea, a condition that causes him to briefly stop breathing hundreds of times when asleep....
...The offer for Alliance Healthcare, comprising $6.275bn in cash and 2m AmerisourceBergen shares, comes three years after a potential deal for Walgreens to acquire the pharmaceuticals distributor fell through...
...While pharmaceutical companies are frequently fined by regulators, it is rare for executives to go to jail....
...Additional reporting by James Politi in Washington...
...Johnson & Johnson has agreed to buy biotech group Momenta Pharmaceuticals for $6.5bn in an all-cash deal that will expand the world’s largest healthcare company’s portfolio of treatments for autoimmune disorders...
...over, and poorer countries whose governments are stretched to secure doses for healthcare workers and the most vulnerable....
...Bayer, the German pharmaceutical group, also said it would donate 3m of its malaria tablets, but as they are not approved in the US, they need an emergency authorisation from the FDA....
...The prospect of much lower bond yields — and, crucially, the expectation that central banks will contain any sharp rise — has encouraged investors to boost their exposure to the technology and healthcare...
International Edition